Hospital
The Health Care Authority of the City of Eufaula
The Health Care Authority of the City of Eufaula was paid $1.48M by Medicaid between Dec 2018 and Nov 2024, across 58 billing codes. Its largest line is 99284, emergency room visit (serious) — 31% of everything it billed.
33Billing provider infoTHE HEALTH CARE AUTHORITY OF THE CITY OF EUFAULA
EUFAULA, AL 36027
EUFAULA, AL 36027
33aNPI1730692641assigned 11/14/2017
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.48M
24GClaims54,127
24DCodes billed58
24AFirst – last monthDec 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alabama
Rank by total paid#35 of 77
Median peer was paid$1.13M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 100 | $0.00 | |
| 2019 | 15,378 | $244K | |
| 2020 | 8,849 | $176K | |
| 2021 | 9,984 | $205K | |
| 2022 | 7,278 | $197K | |
| 2023 | 8,057 | $452K | |
| 2024incomplete | 4,481 | $207K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 31% | 7,660 | 6,314 | $457K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 11,054 | 9,105 | $353K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 22% | 1,394 | 1,112 | $328K |
| 80053 | Comprehensive metabolic panel | 3.5% | 6,218 | 4,907 | $52K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.4% | 875 | 816 | $51K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.9% | 6,613 | 5,114 | $43K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.8% | 957 | 776 | $27K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.8% | 961 | 893 | $27K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 1,822 | 831 | $19K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 559 | 498 | $18K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 472 | 395 | $13K |
| 81001 | <1% | 3,620 | 2,825 | $10K |
46 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,184 | $9K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,872 | $8K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 202 | $7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 155 | $7K |
| 81025 | <1% | 1,442 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 102 | $4K |
| 87634 | <1% | 67 | $4K | |
| 83735 | <1% | 724 | $4K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 137 | $4K |
| 80061 | Lipid panel | <1% | 227 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 188 | $3K |
| 87071 | <1% | 627 | $3K | |
| 0002A | <1% | 86 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 134 | $2K |
| 0001A | <1% | 91 | $2K | |
| 84703 | <1% | 369 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 238 | $2K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 14 | $1K |
| 74018 | <1% | 174 | $1K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 14 | $1K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 12 | $1K |
| 81003 | <1% | 532 | $1K | |
| 84484 | <1% | 183 | $1K | |
| 86756 | <1% | 46 | $797.58 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 91 | $781.54 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 584 | $735.95 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 66 | $593.12 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 46 | $561.40 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 72 | $501.43 |
| 97597 | <1% | 82 | $483.94 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 261 | $314.24 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $301.63 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 551 | $300.56 |
| 83880 | <1% | 12 | $293.58 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 324 | $251.20 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12 | $223.92 |
| 83690 | <1% | 27 | $222.10 | |
| 83605 | <1% | 36 | $168.15 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 16 | $55.52 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 19 | $20.56 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 84 | $8.60 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 27 | $3.39 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 155 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 101 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 448 | $0.00 |
| 99441 | 0% | 75 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKOZAR, MICHAEL (CEO)
| Provider | Location | Paid |
|---|---|---|
| Northwest Florida Healthcare, INC. | Chipley, FL | $224K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.